Shumin Fu

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Metastatic Colorectal Cancer

Top Venues

Current oncology (Toronto, Ont.)

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen, Shenglan Huang, Dan Li, Yaqin Lv, Jianbing Wu
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. Cancer medicine 13 (9) (2024)
Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen, Shenglan Huang, Dan Li, Yaqin Lv, Jianbing Wu
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. Cancer medicine 13 (9) (2024)
Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen, Shenglan Huang, Dan Li, Yaqin Lv, Jianbing Wu
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. Cancer medicine 13 (9) (2024)
Dan Li, Shenglan Huang, Chen Luo, Yongkang Xu, Shumin Fu, Kan Liu, Jianbing Wu
CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma. Current oncology (Toronto, Ont.) 30 (3) (2023)
Dan Li, Shenglan Huang, Chen Luo, Yongkang Xu, Shumin Fu, Kan Liu, Jianbing Wu
CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma. Current oncology (Toronto, Ont.) 30 (3) (2023)
Dan Li, Shenglan Huang, Chen Luo, Yongkang Xu, Shumin Fu, Kan Liu, Jianbing Wu
CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma. Current oncology (Toronto, Ont.) 30 (3) (2023)